Convergent evolution has seen several SARS-CoV-2 sub-lineages of JN.1.* acquire the Spike F456L and R346T mutations aka "FLiRT".
The first chart shows the 9 leading countries by volume, the 2nd chart shows the next 9.
🧵
The designated lineages so far are JN.1.16.1, KP.1.1.*, KP.2.*, KR.1, KS.1 and KU.2. So 6 different evolutionary paths to arrive at the same advantageous combination, in just a few months.
Our collective global variant evolution engine (featuring billions of infections with millions of chronic infections) is efficiently churning along, providing endless surprises.
Convergent evolution has seen several SARS-CoV-2 sub-lineages of JN.1.* acquire the Spike F456L and R346T mutations aka "FLiRT".
The JN.1.* + "FLiRT" lineages have been most successful in Japan (30%), Singapore (23%) and the United States (16%).
🧵
The frequency in the United States has grown to 16%. For recent dates (roughly March 8 onwards), "community transmission" (non-travel related) samples are now the majority.
Globally, JN.1.* + "FLiRT" is still showing a very strong growth advantage of 11% per day (77% per week) over other BA.2.86.* "Pirola" (including JN.1.*) samples since February.
Convergent evolution has seen several SARS-CoV-2 sub-lineages of JN.1.* acquire the Spike F456L and R346T mutations aka "FLiRT".
The JN.1.* + "FLiRT" lineages have been most successful in Singapore (23%) and the United States (10%).
🧵
The designated lineages so far are JN.1.16.1, KP.1.1, KP.2, KR.1 and KS.1.
Globally, JN.1.* + "FLiRT" is showing a very strong growth advantage of 13% per day (90% per week) over other BA.2.86.* "Pirola" (including JN.1.*) samples since February. That predicts a crossover in late March.
Convergent evolution has seen several SARS-CoV-2 sub-lineages of JN.1.* acquire the Spike F456L and R346T mutations aka "tiLT".
The designated lineages so far are KP.1.1, KP.2 and KR.1.
The "tiLT" lineages have been most successful in Singapore (24%) and the USA (7%).
🧵
Here's a map showing the remarkable global spread of JN.1.* + "tiLT". Just under 200 samples have been reported mostly since January, from 23 countries on every continent.
Locations are approximate - typically country and state/province.
Here are the leading US states reporting JN.1.* + "tiLT".
It has been most successful in Virginia (38%), Washington (13%) and New York (10%).
Around 15% of the US samples were collected at airport screening. So it seems community transmission is well underway.
The new KP.2 lineage of SARS-CoV-2 is showing signs of spread. It was first detected in samples collected in early January from Assam, India. It has since showed up in NZ, across North America, Europe and Asia.
Here's an animated map showing the spread of the KP.2 lineage.
🧵
Locations are approximate - typically country and state/province.
Samples from India dried up during January, so it's unclear if KP.2 is still spreading there.
As the lineage designation has not yet flowed through to Nextclade, I'm approximating it by searching for samples with the characteristic mutations.
The new XDQ lineage of SARS-CoV-2 is showing signs of spread. It was first detected in a sample collected in mid-November from Berlin. Within a week it appeared in South Korea, where it has been most successful (30%).
🧵
Here's the variant picture for South Korea. While XDQ's growth against BA.2.86.* "Pirola" looks dramatic, note that the sample volumes are quite low for those recent dates (grey column chart).
So there's still a possibility this is an isolated super-spreader event, and it might yet be swamped by BA.2.86.* (mostly JN.1).